From the Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 29, New York, NY 10065 (N.H., M.E.H., A.E., R.B.); Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil (A.I.d.O., B.C.d.O., J.A.B.A.F., G.L.P.M., M.R.M.); Department of Radiology, University of São Paulo, São Paulo, Brazil (A.I.d.O., G.L.P.M., M.R.M.); and Department of Abdominal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (K.M.E.).
Radiographics. 2022 Oct;42(6):1670-1689. doi: 10.1148/rg.220022.
The treatment planning for patients with hepatocellular carcinoma (HCC) relies predominantly on tumor burden, clinical performance, and liver function test results. Curative treatments such as resection, liver transplantation, and ablative therapies of small lesions should be considered for all patients with HCC. However, many patients are ineligible for these treatments owing to advanced disease stage and comorbidities. Despite efforts to increase screening, early-stage HCC remains difficult to diagnose, which decreases the possibility of curative therapies. In this context, local-regional treatment of HCC is accepted as a form of curative therapy in selected patients with early-stage disease, as a therapeutic option in patients who are not eligible to undergo curative therapies, as a downstaging approach to decrease tumor size toward meeting the criteria for liver transplantation, and as a bridging therapy to avoid tumor growth while the patient is on the waiting list for liver transplantation. The authors review the indications, types, mechanism of action, and possible complications of local-regional treatment, as well as the expected postprocedural imaging features of HCC. Furthermore, they discuss the role of imaging in pre- and postprocedural settings, provide guidance on how to assess treatment response, and review the current limitations of imaging assessment. Finally, the authors summarize the potential future directions with imaging tools that may add value to contemporary practice at response assessment and imaging biomarkers for patient selection, treatment response, and prognosis. RSNA, 2022.
肝细胞癌(HCC)患者的治疗计划主要依赖于肿瘤负荷、临床表现和肝功能试验结果。所有 HCC 患者均应考虑采用根治性治疗,如切除术、肝移植和小病灶消融治疗。然而,由于疾病晚期和合并症,许多患者不符合这些治疗条件。尽管努力增加筛查,但早期 HCC 仍然难以诊断,这降低了根治性治疗的可能性。在这种情况下,局部区域治疗 HCC 被认为是早期疾病患者的一种根治性治疗形式,是不符合根治性治疗条件患者的一种治疗选择,是一种降期方法,可使肿瘤缩小以符合肝移植标准,也是一种桥接治疗方法,可避免肿瘤在等待肝移植期间生长。作者回顾了局部区域治疗的适应证、类型、作用机制和可能的并发症,以及 HCC 术后的预期影像学特征。此外,他们还讨论了影像学在术前和术后的作用,提供了评估治疗反应的指导,并回顾了目前影像学评估的局限性。最后,作者总结了影像学工具的潜在未来发展方向,这些工具可能在评估反应和影像学生物标志物以选择患者、评估治疗反应和预后方面增加当代实践的价值。RSNA,2022 年。